On Jul 03, 2025, Norvatis announced results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
On Jul 03, 2025, Norvatis announced results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
byBoston UniversityCredit: Pixabay/CC0 Public DomainCurrent medical guidelines discourage the use of combined oral contraceptives (COCs) among people who experience migraine with aura—a type of migrai
byBoston UniversityCredit: Pixabay/CC0 Public DomainCurrent medical guidelines discourage the use of combined oral contraceptives (COCs) among people who experience migraine with aura—a type of migrai